X4 Pharmaceuticals announced that the European Commission has granted marketing authorization for its oral CXCR4 antagonist, XOLREMDI (mavorixafor), for the treatment of WHIM syndrome in the European Union. The approval, issued on April 29 2026, follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) and represents the first regulatory endorsement of the drug outside the United States.
Under the licensing agreement signed in January 2025, X4 will partner with Norgine to commercialize XOLREMDI in Europe, Australia, and New Zealand. The deal provides X4 with up to €226 million in milestone payments and mid‑twenty percent royalties on future net sales in the licensed territories, while the company retains U.S. commercial rights for the larger chronic neutropenia market. The partnership expands X4’s commercial reach and delivers non‑dilutive funding that strengthens its balance sheet.
The EU approval is a strategic lever for X4’s pipeline. By securing a second‑market launch for its lead asset, the company can use the resulting cash flow and market validation to fund its Phase 3 4WARD trial in chronic neutropenia. The 4WARD study, which is expected to complete enrollment in Q3 2026 and deliver top‑line data in late 2026, could broaden mavorixafor’s therapeutic portfolio and reinforce X4’s positioning as a rare‑disease platform.
Management highlighted the significance of the milestone. "The approval of mavorixafor in the European Union marks an important step in extending access to XOLREMDI beyond the United States and providing a new, targeted therapeutic option to patients living with WHIM syndrome, an ultra‑rare hematologic disorder," said Adam Craig, M.D., Ph.D., Executive Chairman of X4 Pharmaceuticals. "We look forward to working with Norgine, our commercial partner in Europe, to enable patient access to mavorixafor to treat this devastating condition. In addition, we are now running a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenia to further explore its potential benefit across multiple diseases." Janneke van der Kamp, CEO of Norgine, added, "The approval of XOLREMDI® in the European Union marks a meaningful milestone for people living with WHIM syndrome, an ultra‑rare condition that, until now, has had no approved treatment options."
The announcement was well received by investors, who viewed the regulatory success and the robust Norgine partnership as key drivers of future revenue growth. The deal’s potential €226 million milestone payments and mid‑twenty percent royalties provide a significant upside, while the EU launch expands the drug’s addressable market and supports the company’s broader pipeline strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.